U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C8H7O2.Na
Molecular Weight 158.1297
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of Sodium phenylacetate

SMILES

[Na+].[O-]C(=O)CC1=CC=CC=C1

InChI

InChIKey=HZOREEUASZHZBI-UHFFFAOYSA-M
InChI=1S/C8H8O2.Na/c9-8(10)6-7-4-2-1-3-5-7;/h1-5H,6H2,(H,9,10);/q;+1/p-1

HIDE SMILES / InChI

Molecular Formula C8H7O2
Molecular Weight 135.14
Charge -1
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula Na
Molecular Weight 22.9898
Charge 1
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment: description was created based on several sources, including: https://clinicaltrials.gov/ct2/show/NCT00003241?term=Phenylacetic+acid&rank=3 https://en.wikipedia.org/wiki/Phenylacetic_acid

Phenylacetic acid (abr. PAA and synonyms are: α-toluic acid, benzeneacetic acid, alpha tolylic acid, 2-phenylacetic acid, β-phenylacetic acid) is an organic compound containing a phenyl functional group and acarboxylic acid functional group. Because it is used in the illicit production of phenylacetone (used in the manufacture of substituted amphetamines), it is subject to controls in countries including the United States and China Phenylacetic acid is used in some perfumes, possessing a honey-like odor in low concentrations, and is also used in penicillin G production. It is also employed to treat type II hyperammonemia to help reduce the amounts of ammonia in a patient's bloodstream by forming phenylacetyl-CoA, which then reacts with nitrogen-rich glutamine to form phenylacetylglutamine. This compound is then secreted by the patient's body. In Phase 2 of clinical research it investigated in the treatment of Brain and Central Nervous System Tumors.

CNS Activity

Curator's Comment: Known to be CNS penetrant in cat. Human data not available. Labeled phenylacetic acid (14C-PAA) penetrates blood-cerebrospinal fluid (CSF) barrier in cats only under a high gradient of concentration

Approval Year

Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
AMMONUL

Approved Use

Sodium Phenylacetate and Sodium Benzoate Injection, 10%/10% is a nitrogen binding agent indicated as adjunctive therapy for the treatment of acute hyperammonemia and associated encephalopathy in patients with deficiencies in enzymes of the urea cycle.

Launch Date

2005
Primary
Unknown

Approved Use

Unknown
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
2225 μM
3.75 g/m² single, intravenous
dose: 3.75 g/m²
route of administration: Intravenous
experiment type: SINGLE
co-administered: SODIUM BENZOATE
PHENYLACETIC ACID plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
3022 μM
5.5 g/m² single, intravenous
dose: 5.5 g/m²
route of administration: Intravenous
experiment type: SINGLE
co-administered: SODIUM BENZOATE
PHENYLACETIC ACID plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
281 μM
3.75 g/m² single, intravenous
dose: 3.75 g/m²
route of administration: Intravenous
experiment type: SINGLE
co-administered: SODIUM BENZOATE
PHENYLACETYLGLUTAMINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
15004 μM × h
3.75 g/m² single, intravenous
dose: 3.75 g/m²
route of administration: Intravenous
experiment type: SINGLE
co-administered: SODIUM BENZOATE
PHENYLACETIC ACID plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
28156 μM × h
5.5 g/m² single, intravenous
dose: 5.5 g/m²
route of administration: Intravenous
experiment type: SINGLE
co-administered: SODIUM BENZOATE
PHENYLACETIC ACID plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
2047 μM × h
3.75 g/m² single, intravenous
dose: 3.75 g/m²
route of administration: Intravenous
experiment type: SINGLE
co-administered: SODIUM BENZOATE
PHENYLACETYLGLUTAMINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
0.44%
SODIUM PHENYLACETATE plasma
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
5.5 g/m2 1 times / day multiple, intravenous
Recommended
Dose: 5.5 g/m2, 1 times / day
Route: intravenous
Route: multiple
Dose: 5.5 g/m2, 1 times / day
Co-administed with::
Sodium Benzoate, i.v(5.5 g/m2)
Arginine HCl, i.v(200-600 mg/kg)
Sources: Page: p.11
unhealthy, 0 - 53
n = 316
Health Status: unhealthy
Condition: Hyperammonemia
Age Group: 0 - 53
Sex: M+F
Population Size: 316
Sources: Page: p.11
Disc. AE: Metabolic acidosis, Injection site reactions...
AEs leading to
discontinuation/dose reduction:
Metabolic acidosis (< 1%)
Injection site reactions (< 1%)
Bradycardia (0.32%)
Abdominal distension (0.32%)
Injection site extravasation (0.32%)
Hemorrhage injection site (0.32%)
Blister (0.32%)
Subdural hematoma (0.32%)
Hyperammonemia (0.32%)
Hypoglycemia (0.32%)
Clonus (0.32%)
Coma (0.32%)
Increased intracranial pressure (0.32%)
Hypercapnia (0.32%)
Kussmaul respiration (0.32%)
Respiratory distress (0.32%)
Respiratory failure (0.32%)
Pruritis (0.32%)
Maculo-papular rash (0.32%)
Sources: Page: p.11
300 mg/kg 1 times / day multiple, intravenous (max)
Recommended
Dose: 300 mg/kg, 1 times / day
Route: intravenous
Route: multiple
Dose: 300 mg/kg, 1 times / day
Co-administed with::
Sodium Benzoate, i.v(5.5 g/m2)
Arginine HCl, i.v(200-600 mg/kg)
Sources: Page: p.8
unhealthy
Health Status: unhealthy
Condition: Cancer
Sources: Page: p.8
Other AEs: Neurotoxicity...
AEs

AEs

AESignificanceDosePopulation
Abdominal distension 0.32%
Disc. AE
5.5 g/m2 1 times / day multiple, intravenous
Recommended
Dose: 5.5 g/m2, 1 times / day
Route: intravenous
Route: multiple
Dose: 5.5 g/m2, 1 times / day
Co-administed with::
Sodium Benzoate, i.v(5.5 g/m2)
Arginine HCl, i.v(200-600 mg/kg)
Sources: Page: p.11
unhealthy, 0 - 53
n = 316
Health Status: unhealthy
Condition: Hyperammonemia
Age Group: 0 - 53
Sex: M+F
Population Size: 316
Sources: Page: p.11
Blister 0.32%
Disc. AE
5.5 g/m2 1 times / day multiple, intravenous
Recommended
Dose: 5.5 g/m2, 1 times / day
Route: intravenous
Route: multiple
Dose: 5.5 g/m2, 1 times / day
Co-administed with::
Sodium Benzoate, i.v(5.5 g/m2)
Arginine HCl, i.v(200-600 mg/kg)
Sources: Page: p.11
unhealthy, 0 - 53
n = 316
Health Status: unhealthy
Condition: Hyperammonemia
Age Group: 0 - 53
Sex: M+F
Population Size: 316
Sources: Page: p.11
Bradycardia 0.32%
Disc. AE
5.5 g/m2 1 times / day multiple, intravenous
Recommended
Dose: 5.5 g/m2, 1 times / day
Route: intravenous
Route: multiple
Dose: 5.5 g/m2, 1 times / day
Co-administed with::
Sodium Benzoate, i.v(5.5 g/m2)
Arginine HCl, i.v(200-600 mg/kg)
Sources: Page: p.11
unhealthy, 0 - 53
n = 316
Health Status: unhealthy
Condition: Hyperammonemia
Age Group: 0 - 53
Sex: M+F
Population Size: 316
Sources: Page: p.11
Clonus 0.32%
Disc. AE
5.5 g/m2 1 times / day multiple, intravenous
Recommended
Dose: 5.5 g/m2, 1 times / day
Route: intravenous
Route: multiple
Dose: 5.5 g/m2, 1 times / day
Co-administed with::
Sodium Benzoate, i.v(5.5 g/m2)
Arginine HCl, i.v(200-600 mg/kg)
Sources: Page: p.11
unhealthy, 0 - 53
n = 316
Health Status: unhealthy
Condition: Hyperammonemia
Age Group: 0 - 53
Sex: M+F
Population Size: 316
Sources: Page: p.11
Coma 0.32%
Disc. AE
5.5 g/m2 1 times / day multiple, intravenous
Recommended
Dose: 5.5 g/m2, 1 times / day
Route: intravenous
Route: multiple
Dose: 5.5 g/m2, 1 times / day
Co-administed with::
Sodium Benzoate, i.v(5.5 g/m2)
Arginine HCl, i.v(200-600 mg/kg)
Sources: Page: p.11
unhealthy, 0 - 53
n = 316
Health Status: unhealthy
Condition: Hyperammonemia
Age Group: 0 - 53
Sex: M+F
Population Size: 316
Sources: Page: p.11
Hemorrhage injection site 0.32%
Disc. AE
5.5 g/m2 1 times / day multiple, intravenous
Recommended
Dose: 5.5 g/m2, 1 times / day
Route: intravenous
Route: multiple
Dose: 5.5 g/m2, 1 times / day
Co-administed with::
Sodium Benzoate, i.v(5.5 g/m2)
Arginine HCl, i.v(200-600 mg/kg)
Sources: Page: p.11
unhealthy, 0 - 53
n = 316
Health Status: unhealthy
Condition: Hyperammonemia
Age Group: 0 - 53
Sex: M+F
Population Size: 316
Sources: Page: p.11
Hyperammonemia 0.32%
Disc. AE
5.5 g/m2 1 times / day multiple, intravenous
Recommended
Dose: 5.5 g/m2, 1 times / day
Route: intravenous
Route: multiple
Dose: 5.5 g/m2, 1 times / day
Co-administed with::
Sodium Benzoate, i.v(5.5 g/m2)
Arginine HCl, i.v(200-600 mg/kg)
Sources: Page: p.11
unhealthy, 0 - 53
n = 316
Health Status: unhealthy
Condition: Hyperammonemia
Age Group: 0 - 53
Sex: M+F
Population Size: 316
Sources: Page: p.11
Hypercapnia 0.32%
Disc. AE
5.5 g/m2 1 times / day multiple, intravenous
Recommended
Dose: 5.5 g/m2, 1 times / day
Route: intravenous
Route: multiple
Dose: 5.5 g/m2, 1 times / day
Co-administed with::
Sodium Benzoate, i.v(5.5 g/m2)
Arginine HCl, i.v(200-600 mg/kg)
Sources: Page: p.11
unhealthy, 0 - 53
n = 316
Health Status: unhealthy
Condition: Hyperammonemia
Age Group: 0 - 53
Sex: M+F
Population Size: 316
Sources: Page: p.11
Hypoglycemia 0.32%
Disc. AE
5.5 g/m2 1 times / day multiple, intravenous
Recommended
Dose: 5.5 g/m2, 1 times / day
Route: intravenous
Route: multiple
Dose: 5.5 g/m2, 1 times / day
Co-administed with::
Sodium Benzoate, i.v(5.5 g/m2)
Arginine HCl, i.v(200-600 mg/kg)
Sources: Page: p.11
unhealthy, 0 - 53
n = 316
Health Status: unhealthy
Condition: Hyperammonemia
Age Group: 0 - 53
Sex: M+F
Population Size: 316
Sources: Page: p.11
Increased intracranial pressure 0.32%
Disc. AE
5.5 g/m2 1 times / day multiple, intravenous
Recommended
Dose: 5.5 g/m2, 1 times / day
Route: intravenous
Route: multiple
Dose: 5.5 g/m2, 1 times / day
Co-administed with::
Sodium Benzoate, i.v(5.5 g/m2)
Arginine HCl, i.v(200-600 mg/kg)
Sources: Page: p.11
unhealthy, 0 - 53
n = 316
Health Status: unhealthy
Condition: Hyperammonemia
Age Group: 0 - 53
Sex: M+F
Population Size: 316
Sources: Page: p.11
Injection site extravasation 0.32%
Disc. AE
5.5 g/m2 1 times / day multiple, intravenous
Recommended
Dose: 5.5 g/m2, 1 times / day
Route: intravenous
Route: multiple
Dose: 5.5 g/m2, 1 times / day
Co-administed with::
Sodium Benzoate, i.v(5.5 g/m2)
Arginine HCl, i.v(200-600 mg/kg)
Sources: Page: p.11
unhealthy, 0 - 53
n = 316
Health Status: unhealthy
Condition: Hyperammonemia
Age Group: 0 - 53
Sex: M+F
Population Size: 316
Sources: Page: p.11
Kussmaul respiration 0.32%
Disc. AE
5.5 g/m2 1 times / day multiple, intravenous
Recommended
Dose: 5.5 g/m2, 1 times / day
Route: intravenous
Route: multiple
Dose: 5.5 g/m2, 1 times / day
Co-administed with::
Sodium Benzoate, i.v(5.5 g/m2)
Arginine HCl, i.v(200-600 mg/kg)
Sources: Page: p.11
unhealthy, 0 - 53
n = 316
Health Status: unhealthy
Condition: Hyperammonemia
Age Group: 0 - 53
Sex: M+F
Population Size: 316
Sources: Page: p.11
Maculo-papular rash 0.32%
Disc. AE
5.5 g/m2 1 times / day multiple, intravenous
Recommended
Dose: 5.5 g/m2, 1 times / day
Route: intravenous
Route: multiple
Dose: 5.5 g/m2, 1 times / day
Co-administed with::
Sodium Benzoate, i.v(5.5 g/m2)
Arginine HCl, i.v(200-600 mg/kg)
Sources: Page: p.11
unhealthy, 0 - 53
n = 316
Health Status: unhealthy
Condition: Hyperammonemia
Age Group: 0 - 53
Sex: M+F
Population Size: 316
Sources: Page: p.11
Pruritis 0.32%
Disc. AE
5.5 g/m2 1 times / day multiple, intravenous
Recommended
Dose: 5.5 g/m2, 1 times / day
Route: intravenous
Route: multiple
Dose: 5.5 g/m2, 1 times / day
Co-administed with::
Sodium Benzoate, i.v(5.5 g/m2)
Arginine HCl, i.v(200-600 mg/kg)
Sources: Page: p.11
unhealthy, 0 - 53
n = 316
Health Status: unhealthy
Condition: Hyperammonemia
Age Group: 0 - 53
Sex: M+F
Population Size: 316
Sources: Page: p.11
Respiratory distress 0.32%
Disc. AE
5.5 g/m2 1 times / day multiple, intravenous
Recommended
Dose: 5.5 g/m2, 1 times / day
Route: intravenous
Route: multiple
Dose: 5.5 g/m2, 1 times / day
Co-administed with::
Sodium Benzoate, i.v(5.5 g/m2)
Arginine HCl, i.v(200-600 mg/kg)
Sources: Page: p.11
unhealthy, 0 - 53
n = 316
Health Status: unhealthy
Condition: Hyperammonemia
Age Group: 0 - 53
Sex: M+F
Population Size: 316
Sources: Page: p.11
Respiratory failure 0.32%
Disc. AE
5.5 g/m2 1 times / day multiple, intravenous
Recommended
Dose: 5.5 g/m2, 1 times / day
Route: intravenous
Route: multiple
Dose: 5.5 g/m2, 1 times / day
Co-administed with::
Sodium Benzoate, i.v(5.5 g/m2)
Arginine HCl, i.v(200-600 mg/kg)
Sources: Page: p.11
unhealthy, 0 - 53
n = 316
Health Status: unhealthy
Condition: Hyperammonemia
Age Group: 0 - 53
Sex: M+F
Population Size: 316
Sources: Page: p.11
Subdural hematoma 0.32%
Disc. AE
5.5 g/m2 1 times / day multiple, intravenous
Recommended
Dose: 5.5 g/m2, 1 times / day
Route: intravenous
Route: multiple
Dose: 5.5 g/m2, 1 times / day
Co-administed with::
Sodium Benzoate, i.v(5.5 g/m2)
Arginine HCl, i.v(200-600 mg/kg)
Sources: Page: p.11
unhealthy, 0 - 53
n = 316
Health Status: unhealthy
Condition: Hyperammonemia
Age Group: 0 - 53
Sex: M+F
Population Size: 316
Sources: Page: p.11
Injection site reactions < 1%
Disc. AE
5.5 g/m2 1 times / day multiple, intravenous
Recommended
Dose: 5.5 g/m2, 1 times / day
Route: intravenous
Route: multiple
Dose: 5.5 g/m2, 1 times / day
Co-administed with::
Sodium Benzoate, i.v(5.5 g/m2)
Arginine HCl, i.v(200-600 mg/kg)
Sources: Page: p.11
unhealthy, 0 - 53
n = 316
Health Status: unhealthy
Condition: Hyperammonemia
Age Group: 0 - 53
Sex: M+F
Population Size: 316
Sources: Page: p.11
Metabolic acidosis < 1%
Disc. AE
5.5 g/m2 1 times / day multiple, intravenous
Recommended
Dose: 5.5 g/m2, 1 times / day
Route: intravenous
Route: multiple
Dose: 5.5 g/m2, 1 times / day
Co-administed with::
Sodium Benzoate, i.v(5.5 g/m2)
Arginine HCl, i.v(200-600 mg/kg)
Sources: Page: p.11
unhealthy, 0 - 53
n = 316
Health Status: unhealthy
Condition: Hyperammonemia
Age Group: 0 - 53
Sex: M+F
Population Size: 316
Sources: Page: p.11
Neurotoxicity
300 mg/kg 1 times / day multiple, intravenous (max)
Recommended
Dose: 300 mg/kg, 1 times / day
Route: intravenous
Route: multiple
Dose: 300 mg/kg, 1 times / day
Co-administed with::
Sodium Benzoate, i.v(5.5 g/m2)
Arginine HCl, i.v(200-600 mg/kg)
Sources: Page: p.8
unhealthy
Health Status: unhealthy
Condition: Cancer
Sources: Page: p.8
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG



OverviewOther

Drug as perpetrator​Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
yes
Tox targets

Tox targets

TargetModalityActivityMetaboliteClinical evidence
PubMed

PubMed

TitleDatePubMed
[Studies on the immobilized penicillin acylase on polymer beads].
2001 Apr
[Determination of degraded products of penicillin by high performance liquid chromatography].
2001 Jan
[Determination of organic acids in cigarette smoke].
2001 Jul
Correlation between microbial enzyme activities in the rumen fluid of sheep under different treatments.
2001 Nov-Dec
Aromatic amino acid biosynthesis and production of related compounds from p-hydroxyphenylpyruvic acid by rumen bacteria, protozoa and their mixture.
2002
Evaluation of strains derived from Escherichia coli W as hosts for the expression of penicillin G-acylase-encoding gene cloned on the recombinant plasmid pKA18.
2002
Serum paraoxonase activity changes in patients with Alzheimer's disease and vascular dementia.
2002 Apr
The role of hydrophobic active-site residues in substrate specificity and acyl transfer activity of penicillin acylase.
2002 Apr
New glycosides from the Japanese fern Hymenophyllum barbatum.
2002 Apr
Aponecrotic, antiangiogenic and antiproliferative effects of a novel dextran derivative on breast cancer growth in vitro and in vivo.
2002 Apr
Effects of cryopreservation and phenylacetate on biological characters of adherent LAK cells from patients with hepatocellular carcinoma.
2002 Apr
Fermentation of cottonseed and other feedstuffs in cattle rumen fluid.
2002 Apr 10
Application of molecular genetics to the diagnosis of lymphoid-rich effusions: study of 95 cases with concomitant immunophenotyping.
2002 Aug
Identification of bacteria in drinking and purified water during the monitoring of a typical water purification system.
2002 Aug 15
Genomic analysis of the aromatic catabolic pathways from Pseudomonas putida KT2440.
2002 Dec
Neonatal presentation of ventricular tachycardia and a Reye-like syndrome episode associated with disturbed mitochondrial energy metabolism.
2002 Dec 30
4-Fluoro-N-butylphenylacetamide: a synthetic phenylacetate derivative that upregulates Bcl-X(S), activates caspase cascade and induces apoptosis in human squamous lung cancer CH27 cells.
2002 Dec 5
Pheromone components of the wheat stem sawfly: identification, electrophysiology, and field bioassay.
2002 Feb
Studies on a soft glycopyrrolate analog, SG-1.
2002 Feb
Investigations into tumor accumulation and peroxisome proliferator activated receptor binding by F-18 and C-11 fatty acids.
2002 Feb
Atorvastatin preferentially reduces LDL-associated platelet-activating factor acetylhydrolase activity in dyslipidemias of type IIA and type IIB.
2002 Feb 1
Structure-activity relationships of novel anti-malarial agents. Part 3: N-(4-acylamino-3-benzoylphenyl)-4-propoxycinnamic acid amides.
2002 Feb 25
Growth inhibition of human melanoma tumor cells by the combination of sodium phenylacetate (NaPA) and substituted dextrans and one NaPA-dextran conjugate.
2002 Jan
[Penicillin G acylase--synthesis, regulation, production].
2002 Jan
The cefT gene of Acremonium chrysogenum C10 encodes a putative multidrug efflux pump protein that significantly increases cephalosporin C production.
2002 Jul
Molecular analysis of aerobic phenylacetate degradation in Azoarcus evansii.
2002 Jul
Polarization IR spectra of the hydrogen bond in phenylacetic acid crystals: H/D isotopic effects temperature and polarization effects.
2002 Jul
Monitoring of enzymatic hydrolysis of penicillin G by pyrolysis-negative ion mass spectrometry.
2002 Jul 1
Identification of phenylbutyrylglutamine, a new metabolite of phenylbutyrate metabolism in humans.
2002 Jun
Immunosuppressant-like effects of phenylbutyrate on growth inhibition of Saccharomyces cerevisiae.
2002 Jun
[Up regulation of phenylacetate to glioma homeobox gene expression].
2002 Mar
Emended descriptions of the genus Micrococcus, Micrococcus luteus (Cohn 1872) and Micrococcus lylae (Kloos et al. 1974).
2002 Mar
Induction and repression of the sty operon in Pseudomonas putida CA-3 during growth on phenylacetic acid under organic and inorganic nutrient-limiting continuous culture conditions.
2002 Mar 5
Paraoxonase Gln-Arg(192) and Leu-Met(55) gene polymorphisms and enzyme activity in a population with a low rate of coronary heart disease.
2002 May
Identification of phenyldecanoic acid as a constituent of triacylglycerols and wax ester produced by Rhodococcus opacus PD630.
2002 May
Characterization of tropane alkaloid aromatic esters that reverse the multidrug-resistance phenotype.
2002 May-Jun
Metabolic physiology of aroma-producing Kluyveromyces marxianus.
2002 Nov
A new phenylacetate-bisphosphonate inhibits breast cancer cell growth by proapoptotic and antiangiogenic effects.
2002 Nov-Dec
Arginine 165/arginine 277 pair in (S)-mandelate dehydrogenase from Pseudomonas putida: role in catalysis and substrate binding.
2002 Oct 15
beta-Cell adaptation to insulin resistance. Increased pyruvate carboxylase and malate-pyruvate shuttle activity in islets of nondiabetic Zucker fatty rats.
2002 Oct 18
Development and substantiation of a liquid chromatographic method for monitoring organic reactions involved in synthesis of 4-methoxyphenylacetic acid.
2002 Oct 4
Successful treatment of severe hyperammonemia using sodium phenylacetate powder prepared in hospital pharmacy.
2002 Sep
[Treatment of methicillin-resistant Staphylococcus aureus (MRSA) as part of biosurgical management of a chronic leg ulcer].
2002 Sep
Aerobic metabolism of phenylacetic acids in Azoarcus evansii.
2002 Sep
Serum paraoxonase: effect of the apolipoprotein composition of HDL and the acute phase response.
2003 Apr
Paraoxonase and susceptibility to organophosphorus poisoning in farmers dipping sheep.
2003 Feb
Potent sigma 1-receptor ligand 4-phenyl-1-(4-phenylbutyl) piperidine provides ischemic neuroprotection without altering dopamine accumulation in vivo in rats.
2003 Feb
Structure-activity relationships of novel anti-malarial agents: part 5. N-(4-acylamino-3-benzoylphenyl)-[5-(4-nitrophenyl)-2-furyl]acrylic acid amides.
2003 Feb 10
Environmental effects caused by olive mill wastewaters: toxicity comparison of low-molecular-weight phenol components.
2003 Feb 12
Dual stereoselectivity of 1-(2'-carboxy)benzyl 2-deoxyglycosides as glycosyl donors in the direct construction of 2-deoxyglycosyl linkages.
2003 Jan 27
Patents

Sample Use Guides

Unknown
Route of Administration: Intravenous
In Vitro Use Guide
Unknown
Substance Class Chemical
Created
by admin
on Fri Dec 15 16:00:52 GMT 2023
Edited
by admin
on Fri Dec 15 16:00:52 GMT 2023
Record UNII
48N6U1781G
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
Sodium phenylacetate
HSDB   MART.   ORANGE BOOK   USAN   VANDF   WHO-DD  
USAN  
Official Name English
SODIUM PHENYLACETATE [MART.]
Common Name English
SODIUM PHENYLACETATE COMPONENT OF AMMONUL
Common Name English
UCEPHAN COMPONENT SODIUM PHENYLACETATE
Common Name English
SODIUM PHENYLACETATE [JAN]
Common Name English
SODIUM PHENYLACETATE [HSDB]
Common Name English
AMMONUL COMPONENT SODIUM PHENYLACETATE
Common Name English
SODIUM PHENYLACETATE [USAN]
Common Name English
SODIUM PHENYLACETATE [ORANGE BOOK]
Common Name English
SODIUM PHENYLACETIC ACID
Common Name English
SODIUM PHENYLACETATE COMPONENT OF UCEPHAN
Common Name English
Sodium phenylacetate [WHO-DD]
Common Name English
NSC-3039
Code English
SODIUM PHENYLACETATE [VANDF]
Common Name English
SODIUM BENZENEACETATE
Systematic Name English
Classification Tree Code System Code
FDA ORPHAN DRUG 197804
Created by admin on Fri Dec 15 16:00:52 GMT 2023 , Edited by admin on Fri Dec 15 16:00:52 GMT 2023
DEA NO. 8791
Created by admin on Fri Dec 15 16:00:52 GMT 2023 , Edited by admin on Fri Dec 15 16:00:52 GMT 2023
EU-Orphan Drug EU/3/19/2166
Created by admin on Fri Dec 15 16:00:52 GMT 2023 , Edited by admin on Fri Dec 15 16:00:52 GMT 2023
NCI_THESAURUS C78275
Created by admin on Fri Dec 15 16:00:52 GMT 2023 , Edited by admin on Fri Dec 15 16:00:52 GMT 2023
Code System Code Type Description
EPA CompTox
DTXSID8059427
Created by admin on Fri Dec 15 16:00:52 GMT 2023 , Edited by admin on Fri Dec 15 16:00:52 GMT 2023
PRIMARY
DAILYMED
48N6U1781G
Created by admin on Fri Dec 15 16:00:52 GMT 2023 , Edited by admin on Fri Dec 15 16:00:52 GMT 2023
PRIMARY
RXCUI
56510
Created by admin on Fri Dec 15 16:00:52 GMT 2023 , Edited by admin on Fri Dec 15 16:00:52 GMT 2023
PRIMARY RxNorm
DRUG BANK
DBSALT001277
Created by admin on Fri Dec 15 16:00:52 GMT 2023 , Edited by admin on Fri Dec 15 16:00:52 GMT 2023
PRIMARY
USAN
AA-69
Created by admin on Fri Dec 15 16:00:52 GMT 2023 , Edited by admin on Fri Dec 15 16:00:52 GMT 2023
PRIMARY
HSDB
5581
Created by admin on Fri Dec 15 16:00:52 GMT 2023 , Edited by admin on Fri Dec 15 16:00:52 GMT 2023
PRIMARY
PUBCHEM
23690424
Created by admin on Fri Dec 15 16:00:52 GMT 2023 , Edited by admin on Fri Dec 15 16:00:52 GMT 2023
PRIMARY
EVMPD
SUB15315MIG
Created by admin on Fri Dec 15 16:00:52 GMT 2023 , Edited by admin on Fri Dec 15 16:00:52 GMT 2023
PRIMARY
NCI_THESAURUS
C66723
Created by admin on Fri Dec 15 16:00:52 GMT 2023 , Edited by admin on Fri Dec 15 16:00:52 GMT 2023
PRIMARY
ECHA (EC/EINECS)
204-052-7
Created by admin on Fri Dec 15 16:00:52 GMT 2023 , Edited by admin on Fri Dec 15 16:00:52 GMT 2023
PRIMARY
FDA UNII
48N6U1781G
Created by admin on Fri Dec 15 16:00:52 GMT 2023 , Edited by admin on Fri Dec 15 16:00:52 GMT 2023
PRIMARY
NSC
3039
Created by admin on Fri Dec 15 16:00:52 GMT 2023 , Edited by admin on Fri Dec 15 16:00:52 GMT 2023
PRIMARY
ChEMBL
CHEMBL1200358
Created by admin on Fri Dec 15 16:00:52 GMT 2023 , Edited by admin on Fri Dec 15 16:00:52 GMT 2023
PRIMARY
SMS_ID
100000078120
Created by admin on Fri Dec 15 16:00:52 GMT 2023 , Edited by admin on Fri Dec 15 16:00:52 GMT 2023
PRIMARY
CAS
114-70-5
Created by admin on Fri Dec 15 16:00:52 GMT 2023 , Edited by admin on Fri Dec 15 16:00:52 GMT 2023
PRIMARY
Related Record Type Details
PARENT -> SALT/SOLVATE
Related Record Type Details
ACTIVE MOIETY